{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T03:24:18Z","timestamp":1774409058600,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T00:00:00Z","timestamp":1470960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1038\/ejhg.2016.95","type":"journal-article","created":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T08:50:59Z","timestamp":1470991859000},"page":"S19-S26","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Finding all BRCA pathogenic mutation carriers: best practice models"],"prefix":"10.1038","volume":"24","author":[{"given":"Nicoline","family":"Hoogerbrugge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolijn CJ","family":"Jongmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,12]]},"reference":[{"key":"BFejhg201695_CR1","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen S, Parmigiani G : Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329\u20131333.","journal-title":"J Clin Oncol"},{"key":"BFejhg201695_CR2","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D et al: Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105: 812\u2013822.","journal-title":"J Natl Cancer Inst"},{"key":"BFejhg201695_CR3","unstructured":"National Institute of Health and Care Excellence (NICE): Clinical guideline 164: familial breast cancer. Last update 2013. Available at \n                    www.nice.org.uk\/guidance\/cg164\n                    \n                   (accessed on 27 April 2015)."},{"key":"BFejhg201695_CR4","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN): SIGN Guideline No 135 Management of Epithelial Ovarian Cancer. Edinburgh: SIGN, 2013."},{"key":"BFejhg201695_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12687-011-0042-4","volume":"2","author":"D Gadzicki","year":"2011","unstructured":"Gadzicki D, Evans DG, Harris H et al: Genetic testing for familial\/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Community Genet 2011; 2: 53\u201369.","journal-title":"J Community Genet"},{"key":"BFejhg201695_CR6","first-page":"1505","volume":"80","author":"M Lambert","year":"2009","unstructured":"Lambert M : Guidelines for managing hereditary breast and ovarian cancer syndrome. Am Fam Physician 2009; 80: 1505\u20131507.","journal-title":"Am Fam Physician"},{"key":"BFejhg201695_CR7","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","volume":"22","author":"TR Rebbeck","year":"2004","unstructured":"Rebbeck TR, Friebel T, Lynch HT et al: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22: 1055\u20131062.","journal-title":"J Clin Oncol"},{"key":"BFejhg201695_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"TR Rebbeck","year":"2009","unstructured":"Rebbeck TR, Kauff ND, Domchek SM : Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101: 80\u201387.","journal-title":"J Natl Cancer Inst"},{"key":"BFejhg201695_CR9","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C et al: BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012; 30: 2654\u20132663.","journal-title":"J Clin Oncol"},{"key":"BFejhg201695_CR10","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","volume":"28","author":"BT Hennessy","year":"2010","unstructured":"Hennessy BT, Timms KM, Carey MS et al: Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010; 28: 3570\u20133576.","journal-title":"J Clin Oncol"},{"key":"BFejhg201695_CR11","first-page":"dju089","volume":"106","author":"JM Lee","year":"2014","unstructured":"Lee JM, Hays JL, Annunziata CM et al: Phase I\/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst 2014; 106: dju089.","journal-title":"J Natl Cancer Inst"},{"key":"BFejhg201695_CR12","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","volume":"20","author":"KP Pennington","year":"2014","unstructured":"Pennington KP, Walsh T, Harrell MI et al: Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014; 20: 764\u2013775.","journal-title":"Clin Cancer Res"},{"key":"BFejhg201695_CR13","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1016\/j.ejca.2004.09.008","volume":"40","author":"T Rafnar","year":"2004","unstructured":"Rafnar T, Benediktsdottir KR, Eldon BJ et al: BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study. Eur J Cancer 2004; 40: 2788\u20132793.","journal-title":"Eur J Cancer"},{"key":"BFejhg201695_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/sj.ejhg.5200652","volume":"9","author":"L Sarantaus","year":"2001","unstructured":"Sarantaus L, Vahteristo P, Bloom E et al: BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients. Eur J Hum Genet 2001; 9: 424\u2013430.","journal-title":"Eur J Hum Genet"},{"key":"BFejhg201695_CR15","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJM199704173361602","volume":"336","author":"JF Stratton","year":"1997","unstructured":"Stratton JF, Gayther SA, Russell P et al: Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997; 336: 1125\u20131130.","journal-title":"N Engl J Med"},{"key":"BFejhg201695_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/humu.10090","volume":"20","author":"H Yazici","year":"2002","unstructured":"Yazici H, Glendon G, Yazici H et al: BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases. Hum Mutat 2002; 20: 28\u201334.","journal-title":"Hum Mutat"},{"key":"BFejhg201695_CR17","unstructured":"Eccles D, Garcia EG, Balma\u00f1a J et al: Selecting Ovarian Cancer Patients for BRCA Mutation Testing: Findings from Guidelines and Literature Review. in Poster at the Conference of the British Society of Genetic Medicine (BSGM); 22\u201324 September 2014; Liverpool, UK."},{"key":"BFejhg201695_CR18","doi-asserted-by":"publisher","first-page":"vi31","DOI":"10.1093\/annonc\/mdr373","volume":"22","author":"J Balma\u00f1a","year":"2011","unstructured":"Balma\u00f1a J, Diez O, Rubio IT, Cardoso F : BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22: vi31\u2013vi34.","journal-title":"Ann Oncol"},{"key":"BFejhg201695_CR19","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.6004\/jnccn.2014.0127","volume":"12","author":"MB Daly","year":"2014","unstructured":"Daly MB, Pilarski R, Axilbund JE et al: Genetic\/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw 2014; 12: 1326\u20131338.","journal-title":"J Natl Compr Canc Netw"},{"key":"BFejhg201695_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13073-015-0128-4","volume":"7","author":"I Slade","year":"2015","unstructured":"Slade I, Riddell D, Turnbull C, Hanson H, Rahman N : Development of cancer genetic services in the UK: A national consultation. Genome Med 2015; 7: 18.","journal-title":"Genome Med"},{"key":"BFejhg201695_CR21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/PPO.0b013e318238f579","volume":"17","author":"KL Smith","year":"2011","unstructured":"Smith KL, Isaacs C : BRCA mutation testing in determining breast cancer therapy. Cancer J 2011; 17: 492\u2013499.","journal-title":"Cancer J"},{"key":"BFejhg201695_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1897-4287-2-1-19","volume":"2","author":"I van Oostrom","year":"2004","unstructured":"van Oostrom I, Tibben A : A counselling model for BRCA1\/2 genetic susceptibility testing. Hered Cancer Clin Pract 2004; 2: 19\u201323.","journal-title":"Hered Cancer Clin Pract"},{"key":"BFejhg201695_CR23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10689-012-9524-8","volume":"11","author":"HS Vig","year":"2012","unstructured":"Vig HS, Wang C : The evolution of personalized cancer genetic counseling in the era of personalized medicine. Fam Cancer 2012; 11: 539\u2013544.","journal-title":"Fam Cancer"},{"key":"BFejhg201695_CR24","doi-asserted-by":"publisher","first-page":"g1200","DOI":"10.1136\/bmj.g1200","volume":"348","author":"S Arie","year":"2014","unstructured":"Arie S : Routine testing for women with ovarian cancer. BMJ 2014; 348: g1200.","journal-title":"BMJ"},{"key":"BFejhg201695_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/jmedgenet-2012-100961","volume":"50","author":"S Moghadasi","year":"2013","unstructured":"Moghadasi S, Hofland N, Wouts JN et al: Variants of uncertain significance in BRCA1 and BRCA2 assessment of in silico analysis and a proposal for communication in genetic counselling. J Med Genet 2013; 50: 74\u201379.","journal-title":"J Med Genet"},{"key":"BFejhg201695_CR26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/codi.12880","volume":"17","author":"N Dekker","year":"2014","unstructured":"Dekker N, Hermens RP, de Wilt JH, van Zelst-Stams WA, Hoogerbrugge N : Improving recognition and referral of patients with an increased familial risk of colorectal cancer: results from a randomised controlled trial. Colorectal Dis 2014; 17: 499\u2013510.","journal-title":"Colorectal Dis"},{"key":"BFejhg201695_CR27","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/bjc.2012.599","volume":"108","author":"A Br\u00e9dart","year":"2013","unstructured":"Br\u00e9dart A, Kop JL, Depauw A et al: Short-term psychological impact of the BRCA1\/2 test result in women with breast cancer according to their perceived probability of genetic predisposition to cancer. Br J Cancer 2013; 108: 1012\u20131020.","journal-title":"Br J Cancer"},{"key":"BFejhg201695_CR28","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1037\/a0014778","volume":"28","author":"JG Hamilton","year":"2009","unstructured":"Hamilton JG, Lobel M, Moyer A : Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. Health Psychol 2009; 28: 510\u2013518.","journal-title":"Health Psychol"},{"key":"BFejhg201695_CR29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/cncr.28879","volume":"121","author":"AM Hirschberg","year":"2015","unstructured":"Hirschberg AM, Chan-Smutko G, Pirl WF : Psychiatric implications of cancer genetic testing. Cancer 2015; 121: 341\u2013360.","journal-title":"Cancer"},{"key":"BFejhg201695_CR30","unstructured":"Bjorvatn C, Aas T, Fiane BE et al: BRCA mutation testing in all newly diagnosed patients with breast or ovarian cancer: the DNA BONus study. Abstract P12.016-M at the European Society of Human Genetics (ESHG); 31 May-3 June 2014; Milan, Italy."},{"key":"BFejhg201695_CR31","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1200\/JCO.2013.51.3226","volume":"32","author":"MD Schwartz","year":"2014","unstructured":"Schwartz MD, Valdimarsdottir HB, Peshkin BN et al: Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol 2014; 32: 618\u2013626.","journal-title":"J Clin Oncol"},{"key":"BFejhg201695_CR32","first-page":"143","volume":"13","author":"AS Sie","year":"2014","unstructured":"Sie AS, van Zelst-Stams WA, Spruijt L et al: More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling. Fam Cancer 2014; 13: 143\u2013151.","journal-title":"Fam Cancer"},{"key":"BFejhg201695_CR33","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2009.27.0660","volume":"28","author":"ME Robson","year":"2010","unstructured":"Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K : American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010; 28: 893\u2013901.","journal-title":"J Clin Oncol"},{"key":"BFejhg201695_CR34","doi-asserted-by":"publisher","first-page":"iv305","DOI":"10.1093\/annonc\/mdu338.7","volume":"25","author":"A George","year":"2014","unstructured":"George A, Smith F, Cloke V et al: Implementation of routine BRCA gene testing of ovarian cancer (OC) patients at Royal Marsden Hospital. Ann Oncol 2014; 25: iv305\u2013iv326.","journal-title":"Ann Oncol"},{"key":"BFejhg201695_CR35","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609\u2013615.","journal-title":"Nature"},{"key":"#cr-split#-BFejhg201695_CR36.1","unstructured":"5. NHS England. Clinical Commissioning Policy: Genetic Testing for BRCA1 and BRCA2 Mutations. October 2015"},{"key":"#cr-split#-BFejhg201695_CR36.2","unstructured":"6. Available at   https:\/\/www.england.nhs.uk\/commissioning\/wp-content\/uploads\/sites\/12\/2015\/10\/e01pb-brca-ovarian-canceroct15.pdf    ."},{"key":"BFejhg201695_CR37","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s10897-012-9519-5","volume":"22","author":"S Salemink","year":"2013","unstructured":"Salemink S, Dekker N, Kets CM, van der Looij E, van Zelst-Stams WA, Hoogerbrugge N : Focusing on patient needs and preferences may improve genetic counseling for colorectal cancer. J Genet Couns 2013; 22: 118\u2013124.","journal-title":"J Genet Couns"},{"key":"BFejhg201695_CR38","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1136\/jmg.40.5.e56","volume":"40","author":"EA Lobb","year":"2003","unstructured":"Lobb EA, Butow PN, Meiser B et al: Women's preferences and consultants' communication of risk in consultations about familial breast cancer: impact on patient outcomes. J Med Genet 2003; 40: e56.","journal-title":"J Med Genet"},{"key":"BFejhg201695_CR39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1200\/JCO.1998.16.1.133","volume":"16","author":"J Audrain","year":"1998","unstructured":"Audrain J, Rimer B, Cella D et al: Genetic counseling and testing for breast-ovarian cancer susceptibility: what do women want? J Clin Oncol 1998; 16: 133\u2013138.","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ejhg201695.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ejhg201695","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ejhg201695.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:17:57Z","timestamp":1684430277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ejhg201695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,12]]},"references-count":40,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["BFejhg201695"],"URL":"https:\/\/doi.org\/10.1038\/ejhg.2016.95","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,12]]},"assertion":[{"value":"12 August 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NH has received payments for consulting and speaker services from AstraZeneca and has attended advisory boards for AstraZeneca. She has also received grant support from AstraZeneca. MCJJ has declared no conflicts.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}